Is Coral Labs. overvalued or undervalued?

As of 13 November 2025, Coral Labs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 9.66, a Price to Book Value of 0.89, and an EV to EBITDA of 4.22. These ratios indicate a strong valuation position compared to its peers, particularly when contrasted with Sun Pharma's PE ratio of 36.15 and Divi's Lab's PE ratio of 70.4, both of which are significantly higher.
The company's financial metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. With a ROCE of 24.89% and a PEG ratio of 0.00, Coral Labs demonstrates efficient capital utilization and growth potential. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -34.52% compared to the Sensex's 8.11%, the underlying fundamentals suggest that Coral Labs is a compelling investment opportunity at its current price of 499.55.